Seragon Pharmaceuticals
Seragon Pharmaceuticals
Company Overview
Our vision is to put good health back into the hands of the consumer by investing in the optimization of human health and longevity through fresh thinking and a progressive approach to biomedical design and state-of-the-art manufacturing. Seragon Pharmaceuticals' orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon's most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon's SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.
Products & Services
Seragon Pharmaceuticals - Main Product
Media Gallery
Seragon Pharmaceuticals Image 1
Team
Richard H
CHIEF EXECUTIVE OFFICER
Richard A. H......, PhD, has 20 years of drug discovery experience in the biotech sector and, most recently, cofounded Aragon Pharmaceuticals in 2009....
Company Stats
Key metrics about Seragon Pharmaceuticals
Fuel Level
Engagement metrics for Seragon Pharmaceuticals
Fuel represents engagement and interest in this company from the Crowdigy community.
Are you the owner of Seragon Pharmaceuticals?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company